Pay in 4 interest-free payments of $6.93 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
The depth feels medical, not bureaucratic no government ID upload, no phone OTP, and the card is only collected at the very end
If this sparks interest, please contact your Affinity Patient Care Coordinator today
TLDR: "Discontinuation of GLP-1RA treatment leads to weight regain, regardless of lifestyle interventions, and should therefore be considered a chronic therapy to prevent weight regain and associated undesirable outcomes related to obesity." Key findings: After stopping liraglutide, patients regained ~2.2 kg After stopping semaglutide/tirzepatide, patients regained ~9.7 kg Weight regain was proportional to initial weight loss Lifestyle changes alone DID NOT prevent regain Implication: GLP-1 receptor agonists are not a short-term solution
Ethics statement The animal study was approved by the experimental protocol was approved by the Institutional Animal Care and Use Committee of Jining Medical University (Approval No
